The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Clinical Trial Planning and Design Services Market by Phase of Trial (Phase I, Phase II, Phase III and Phase IV), Type of Service (Statistical Analysis Plan, eCRF, Site Identification and Selection, Medical Writing and Others), Therapeutic Area (Oncological Disorders, Cardiovascular Disorders, Inflammatory Disorders, Neurological Disorders, and Other Therapeutic Areas), and Geography (North America, Europe, Asia-Pacific, and Rest of the World): Industry Trends and Global Forecasts, 2021-2030

  • Lowest Price Guaranteed From USD 5,899

  • Published
    August 2021

  • Pages
    190

  • View Count
    1133

Example Insights

Clinical-Trial-Planning-and-Design-Services-Market-Context 	Clinical-Trial-Planning-and-Design-Services-Market-List-of-Clinical-Trial-Planning-and-Design-Service-Providers Clinical-Trial-Planning-and-Design-Services-Market-Different-Types-Of-End-Users
Clinical-Trial-Planning-and-Design-Services-Market-Partnerships-and-Collaborations Clinical-Trial-Planning-and-Design-Services-Market-Mergers-and-Acquisitions Clinical-Trial-Planning-and-Design-Services-Market-Competitiveness-Analysis
Clinical-Trial-Planning-and-Design-Services-Market-Various-Business-Strategies Clinical-Trial-Planning-and-Design-Services-Market-Future-Opportunity  

 

Overview

It is a well-known fact that development of a novel therapeutic intervention is both a time and cost intensive process. In fact, several reports have indicated that it can take around 10 years for a prescription medicine to transition from the discovery stage to the market, requiring investments worth over USD 2.5 billion. It is worth mentioning that clinical trials form an integral part of the overall drug development process, as they enable both innovators and regulators to assess the safety and efficacy of a drug candidate.The critical role of these studies can also be verified from the fact that they capture around 50% share of the total time and cost related investments made for the development of drug candidate. However, the conduct of trials is often fraught with  several challenges, including scientific and operational complexity, concerns associated with recruitment and retention of suitable patients, issues related to data handling and increasingly stringent regulatory guidelines. Further, failure of a clinical trial can impose an enormous financial burden on sponsors, estimated to be in the range of USD 800 million (in case of therapies with niche / limited applications) to USD 1.4 billion (for a drug that is anticipated to be a blockbuster). It is further believed that a considerable portion of the losses can be avoided by efficient planning of trials. In other words, effective trial planning and design plays a pivotal role in enabling accurate, safe and timely execution of the study, across all sites. 

Over the years, players engaged in the pharmaceutical industry have often leveraged novel and advanced technologies to address the existing challenges. In a similar manner, clinical trial sponsors are actively assessing available technologies / platforms with the intention of further optimizing the overall process. Recently, the clinical research segment has also witnessed a surge in number of vendors, offering a diverse range of services and solutions for clinical trial planning and design. Moreover, various startups and small firms have entered into collaborations in order to advance their innovations and offer specialized research expertise, services and tools. Additionally, several service providers engaged in this domain have shifted their focus on the development of software in order to automate the process and enable efficient planning and design of clinical trials. The aforementioned initiatives are focused on better facilitating / supporting the drug development process through early stage planning and design. Given the ongoing efforts to improve / expedite the clinical drug development process, we are led to believe that the clinical trial planning and design services market is likely to witness steady growth in the coming years.

The “Clinical Trial Planning and Design Services Market, 2021-2030: Distribution by Phase of Trial (Phase I, Phase II, Phase III and Phase IV), Type of Service (Statistical Analysis Plan, eCRF, Site Identification and Selection, Medical Writing and Others), Therapeutic Area (Oncological Disorders, Cardiovascular Disorders, Inflammatory Disorders, Neurological Disorders, and Other Therapeutic Areas), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)” report features an extensive study of the current market landscape and the likely future potential of the clinical trial planning and design services market, over the next decade. The study also includes an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. Amongst other elements, the report features:

  • A detailed overview of the overall market landscape of players engaged in providing clinical trial planning and design services, along with information on several relevant parameters, such as year of establishment, company size, location of headquarters, types of end-user (pharmaceutical players, medical device developers and biotechnology industry) and type of service(s) offered (PK / PD analysis, study design / protocol development, sample size and power analysis, statistical analysis plan (SAP) development, case report form development (CRF), informed consent documents (ICD), randomization, investigator and site selection, study feasibility and regulatory support service). 
  • An in depth company competitiveness analysis of clinical trial planning and design service providers based on company strength (in terms of experience and company size), and service portfolio strength (such as PK / PD analysis, study design / protocol development, sample size and power analysis, statistical analysis plan (SAP) development, case report form development (CRF), informed consent documents (ICD), randomization, investigator and site selection, study feasibility and regulatory support service).
  • An insightful analysis highlighting the cost saving potential associated with clinical trial planning and design services.   
  • An analysis of the recent partnerships inked between various service providers offering clinical trial planning and design services. Additionally, it includes a brief description of the various types of partnerships models (such as clinical trial design agreements, licensing agreements, and service alliances) that have been adopted by stakeholders engaged in this domain, since 2016. 
  • A detailed analysis of various mergers and acquisitions undertaken by service providers engaged in this domain, during the period 2016-2020, based on several parameters (year of agreement, type of agreement, intracontinental and intercontinental agreement, key value drivers).
  • A proprietary 2×2 representation, highlighting the current market scenario (in terms of existing competition and growth opportunities) across emerging and established market segments.
  • A discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry’s evolution, along with a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall clinical trial planning and design services market.
  • Elaborate profiles of key players engaged in offering clinical trial planning and design services. Each company profile features a brief overview of the company, along with information on its year of establishment, number of employees, location of headquarters, key executives, financial details (if available), service portfolio, recent developments and an informed future outlook.

One of the key objectives of the report was to evaluate the current opportunity and future potential of the clinical trial planning and design service market, over the coming decade. We have also provided an informed estimate on the likely evolution of the market in the short to mid-term and long term, over the period 2021-2030. Additionally, the report features the likely distribution of the current and forecasted opportunity across [A] phase of trial (phase I, phase II, phase III and phase IV), [B] type of service(s) offered (statistical analysis plan, eCRF, site identification and selection, medical writing and others), [C] therapeutic area (oncological disorders, cardiovascular disorders, inflammatory disorders, neurological disorders, and other therapeutic areas) and [D] geography (North America, Europe, Asia-Pacific, and Rest of the World).  In order to account for future uncertainties and add robustness to our forecast model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the key players engaged in offering clinical trial planning and design services, across the world?
  • What are the regulatory guidelines established in different geographies and their requirements related to clinical trial planning and design?
  • What kind of partnership models are most commonly adopted by stakeholders engaged in this industry?
  • What are the key value drivers of the merger and acquisition activity observed within this domain?
  • How is the current and future market opportunity likely to be distributed across key market segments?
  • What are the anticipated future trends related to clinical trial planning and design services?

Contents

Chapter Outlines

Chapter 2 is an executive summary of key insights captured in our research. It offers a high-level view on the current state of the clinical trial planning and design service market and its likely evolution in the mid to long-term. 

Chapter 3 provides a general introduction to clinical trials, featuring insights on the historical evolution of such studies. It further includes a brief introduction to the concept of clinical trial planning and design in this domain, along with the key considerations and fundamentals related to clinical trial planning and design. Furthermore, it provides information on the key challenges associated with this domain. 

Chapter 4 features a discussion on the various guidelines established by major regulatory bodies for clinical trial plan and design approval across North America (US and Canada), Europe (European Union and UK), Asia-Pacific (Australia, China and India).

Chapter 5 provides a detailed overview of the overall market landscape of players engaged in providing clinical trial planning and design services, along with information on several relevant parameters, such as year of establishment, company size, location of headquarters, types of end-user (pharmaceutical players, medical device developers and biotechnology industry) and type of service(s) offered (PK / PD analysis, study design / protocol development, sample size and power analysis, statistical analysis plan (SAP) development, case report form development (CRF), informed consent documents (ICD), randomization, investigator and site selection, study feasibility and regulatory support service).  

Chapter 6 features an in depth company competitiveness analysis of clinical trial planning and design service providers based on company strength (in terms of experience and company size), and service portfolio strength (such as PK / PD analysis, study design / protocol development, sample size and power analysis, statistical analysis plan (SAP) development, case report form development (CRF), informed consent documents (ICD), randomization, investigator and site selection, study feasibility and regulatory support service).

Chapter 7 features and elaborate profiles of key players engaged in offering clinical trial planning and design services. Each company profile features a brief overview of the company, along with information on its year of establishment, number of employees, location of headquarters, key executives, financial details (if available), service portfolio, recent developments and an informed future outlook.

Chapter 8 features an analysis of the recent partnerships inked between various service providers offering clinical trial planning and design services. Additionally, it includes a brief description of the various types of partnerships models (such as clinical trial design agreements, licensing agreements, and service alliances) that have been adopted by stakeholders engaged in this domain, since 2016.

Chapter 9 presents insights from a detailed analysis of various mergers and acquisitions undertaken by service providers engaged in this domain, during the period 2016-2020, based on several parameters (year of agreement, type of agreement, intracontinental and intercontinental agreement, key value drivers).

Chapter 10 features a proprietary 2×2 representation, highlighting the current market scenario (in terms of existing competition and growth opportunities) across emerging and established market segments.

Chapter 11 An insightful analysis highlighting the cost saving potential associated with clinical trial planning and design market.

Chapter 12 features a comprehensive market forecast analysis, highlighting the likely growth of clinical trial planning and design market, for the time period 2021-2030. In order to provide details on the future outlook, our projections have been segmented on the basis of [A] phase of trial (phase I, phase II, phase III and phase IV), [B] type of service (statistical analysis plan, eCRF, site identification and selection, medical writing and others), [C] therapeutic area (oncological disorders, cardiovascular disorders, inflammatory disorders, neurological disorders, and other therapeutic areas), and [D] geography (North America, Europe, Asia-Pacific, and Rest of the World).

Chapter 13 provides a detailed discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry’s evolution, along with a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall clinical trial planning and design services market.

Chapter 14 is a summary of the entire report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 15 is a collection of interview transcripts, these discussions were held with key stakeholders in the industry. These include Bradley Joblin (Study Design and Clinical Development Specialist, Armstrong Clinical) and Jesus N. Sarol and Amandeep Kaur (Senior Research Biostatistician and Research Biostatistician, Interdisciplinary Health Sciences Institute (University of Illinois))

Chapter 16 is an appendix, which presents the list of CROs engaged in offering services in the clinical trial planning and design domain.

Chapter 17 is an appendix, which provides tabulated data and numbers for all the figures included in the report. 

Chapter 18 is an appendix, which contains a list of companies and organizations mentioned in this report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Clinical trials
3.2.1. Historical Evolution of Clinical Trials
3.2.2. Phases of Clinical Development

3.3. Introduction to Clinical Trial Planning and Design
3.3.1. Key Considerations for Clinical Trial Planning
3.3.2. Fundamentals of Clinical Trial Design
3.3.3. Challenges Associated with Clinical Trial Planning and Design

3.4. Concluding Remarks

4. REGULATORY LANDSCAPE
4.1. Chapter Overview

4.2. Regulatory Guidelines in North America
4.2.1. US Scenario
1.2.2. Canadian Scenario

4.3. Regulatory Guidelines in Europe
4.3.1. EU Scenario
4.3.2. UK Scenario

4.4. Regulatory Guidelines in Asia Pacific
4.4.1. Australian Scenario
4.4.2. Chinese Scenario
4.4.3. Indian Scenario 
4.5 Concluding Remarks

5. MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Market Landscape of Industry Players
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size 
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Type of Product
5.2.5 Analysis by Type of Trial Design 
5.2.6. Analysis by Type of Service Offered

5.3. Market Landscape for Non-Industry Players
5.3.1. Analysis by Year of Establishment
5.3.2. Analysis by Company Size 
5.3.3. Analysis by Location of Headquarters 
5.3.4. Analysis by Type of Service Offered

6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Key Assumptions and Parameters

6.3. Methodology
6.3.1. Company Competitiveness: North America
6.3.2. Company Competitiveness: Europe
6.3.3. Company Competitiveness: Asia-Pacific and RoW

6.4. Company Competitiveness: Benchmarking the Capabilities of Leading Players

7. COMPANY PROFILES
7.1. PharmaLex
7.1.1. Company Overview
7.1.2. Service Portfolio
7.1.3. Recent Development and Future Outlook

7.2. Emergo UL
7.2.1. Company Overview
7.2.2. Service Portfolio
7.2.3. Recent Development and Future Outlook

7.3. Cytel
7.3.1. Company Overview
7.3.2. Service Portfolio
7.3.3. Recent Development and Future Outlook

7.4. Health Policy Associate
7.4.1. Company Overview
7.4.2. Service Portfolio
7.4.3. Recent Development and Future Outlook

7.5. CD BioSciences
7.5.1. Company Overview
7.5.2. Service Portfolio
7.5.3. Recent Development and Future Outlook

7.6. LLX Solutions
7.6.1. Company Overview
7.6.2. Service Portfolio
7.6.3. Recent Development and Future Outlook

7.7. SGS
7.7.1. Company Overview
7.7.2. Service Portfolio
7.7.3. Recent Development and Future Outlook 

7.8. ADM Korea
7.8.1. Company Overview
7.8.2. Service Portfolio
7.8.3. Recent Development and Future Outlook 

7.9. ClinAsia
7.9.1. Company Overview
7.9.2. Service Portfolio
7.9.3. Recent Development and Future Outlook

7.10. BioPoint
7.10.1. Company Overview
7.10.2. Service Portfolio
7.10.3. Recent Development and Future Outlook

8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models

8.3. Clinical Trial Planning and Design: Recent Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership 
8.3.3. Analysis by Year and Type of Partnership 
8.3.4. Analysis by Focus Area
8.4. Most Active Players: Analysis by Number of Partnerships

8.5. Analysis by Geography
8.5.1. Country-wise Distribution
8.5.2. Intercontinental and Intracontinental Deals 

9. MERGERS AND ACQUISITIONS
9.1. Chapter Overview
9.2. Merger and Acquisition Models

9.3. Clinical Trial Planning and Design: Mergers and Acquisitions
9.3.1. Analysis by Year of Agreement
9.3.2. Analysis by Type of Agreement
9.3.3. Analysis by Type of Acquisition
9.3.4. Analysis by Geography
9.3.4.1. Region-wise distribution
9.3.4.2. Country-wise distribution
9.3.3. Ownership Type Change Matrix

9.4. Key Value Drivers
9.4.1. Analysis by Key Value Drivers
9.4.2. Analysis by Year of Acquisition and Key Value Drivers

10. ATTRACTIVENESS COMPETETIVENESS MATRIX
10.1. Chapter Overview
10.2. AC Matrix: Overview
10.2.1. Strong Business Segment
10.2.2. Average Business Segment
10.2.3. Weak Business Segment

10.3. Analytical Methodology
10.4. AC Matrix: Clinical Planning and Design Scenario in North America
10.5. AC Matrix: Clinical Planning and Design Scenario in Europe
10.6. AC Matrix: Clinical Planning and Design Scenario in Asia Pacific and Middle East

11. COST SAVING ANALYSIS
11.1. Chapter Overview
11.2. Key Assumptions
11.3. Methodology
11.4. Overall Cost Saving Potential of Clinical Trial Planning and Design, 2021-2030
11.5. Concluding Remarks

12. MARKET FORECAST
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions

12.3. Global Clinical Trial Planning and Design Market
12.3.1. Global Clinical Trial Planning and Design Market: Distribution by Type of Service Offered
12.3.2. Global Clinical Trial Planning and Design Market: Distribution by Therapeutic Area
12.3.3. Global Clinical Trial Planning and Design Market: Distribution by Trial Phase
12.3.4. Global Clinical Trial Planning and Design Market: Distribution by Geography

12.4. Clinical Trial Planning and Design Market in North America
12.4.1. Clinical Trial Planning and Design Market in North America: Distribution by Therapeutic Area
12.4.1.1. Clinical Trial Planning and Design Market for Oncological Disorders in North America, 2021-2030
12.4.1.2. Clinical Trial Planning and Design Market for Neurological Disorders in North America, 2021-2030
12.4.1.3. Clinical Trial Planning and Design Market for Infectious Disorders in North America, 2021-2030
12.4.1.4. Clinical Trial Planning and Design Market for Autoimmune Disorders in North America, 2021-2030
12.4.1.5. Clinical Trial Planning and Design Market for Cardiovascular Disorders in North America, 2021-2030
12.4.1.6. Clinical Trial Planning and Design Market for Respiratory Disorders in North America, 2021-2030
12.4.1.7. Clinical Trial Planning and Design Market for Other Therapeutic Areas in North America, 2021-2030

12.5. Clinical Trial Planning and Design Services Market in Europe
12.5.1. Clinical Trial Planning and Design Services Market: Distribution by Therapeutic Area in Europe
12.5.1.1. Clinical Trial Planning and Design Market for Oncological Disorders in Europe, 2021-2030
12.5.1.2. Clinical Trial Planning and Design Market for Neurological Disorders in Europe, 2021-2030
12.5.1.3. Clinical Trial Planning and Design Market for Infectious Disorders in Europe, 2021-2030
12.5.1.4. Clinical Trial Planning and Design Market for Autoimmune Disorders in Europe, 2021-2030
12.5.1.5. Clinical Trial Planning and Design Market for Cardiovascular Disorders in Europe, 2021-2030
12.5.1.6. Clinical Trial Planning and Design Market for Respiratory Disorders in Europe, 2021-2030
12.5.1.7. Clinical Trial Planning and Design Market for Other Therapeutic Areas in Europe, 2021-2030

12.6. Clinical Trial Planning and Design Services Market in Asia-Pacific
12.6.1. Clinical Trial Planning and Design Services Market: Distribution by Therapeutic Area in Asia-Pacific
12.6.1.1. Clinical Trial Planning and Design Market for Oncological Disorders in Asia-Pacific, 2021-2030
12.6.1.2. Clinical Trial Planning and Design Market for Neurological Disorders in Asia-Pacific, 2021-2030
12.6.1.3. Clinical Trial Planning and Design Market for Infectious Disorders in Asia-Pacific, 2021-2030
12.6.1.4. Clinical Trial Planning and Design Market for Autoimmune Disorders in Asia-Pacific, 2021-2030
12.6.1.5. Clinical Trial Planning and Design Market for Cardiovascular Disorders in Asia-Pacific, 2021-2030
12.6.1.6. Clinical Trial Planning and Design Market for Respiratory Disorders in Asia-Pacific, 2021-2030
12.6.1.7. Clinical Trial Planning and Design Market for Other Therapeutic Areas in Asia-Pacific, 2021-2030

12.7. Clinical Trial Planning and Design Services Market in Latin America
12.8. Clinical Trial Planning and Design Services Market in Middle East North America

13. SWOT ANALYSIS
13.1. Chapter Overview
13.2. Strengths
13.3. Weaknesses
13.4. Opportunities
13.5. Threats
13.6. Comparison of SWOT Factors

14. CONCLUDING REMARKS

15. EXECUTIVE INSIGHTS
15.1 Chapter Overview
15.2 Armstrong Clinical
15.2.1 Company Snapshot
15.2.2 Interview Transcript: Bradley Joblin, Study Design and Clinical Development Specialist

15.3 Interdisciplinary Health Sciences Institute (University of Illinois)
15.3.1 Company Snapshot
15.3.2 Interview Transcript: Jesus N. Sarol Jr (Senior Research Biostatistician) and Amandeep kaur (Research Biostatistician)

16. APPENDIX I: LIST OF CROS

17. APPENDIX II: TABULATED DATA

18. APPENDIX III: LIST OF COMPANIES AND ORGANIZATION

List Of Figures

Figure 3.1 Key Steps Involved in a Clinical Trial
Figure 3.2 Key Considerations for Clinical Trial Planning and Design
Figure 3.3 Key Challenges Associated with Clinical Trial Planning and Design
Figure 5.1 Clinical Trial Planning and Design (Industry Players): Distribution by Year of Establishment
Figure 5.2 Clinical Trial Planning and Design (Industry Players): Distribution by Company Size
Figure 5.3 Clinical Trial Planning and Design (Industry Players): Distribution by Location of Headquarters
Figure 5.4 Clinical Trial Planning and Design (Industry Players): Distribution by Type of Product
Figure 5.5 Clinical Trial Planning and Design (Industry Players): Distribution by Type of Trial Design
Figure 5.6 Clinical Trial Planning and Design (Industry Players): Distribution by Type of Service Offered
Figure 5.7 Clinical Trial Planning and Design (Non-Industry Players): Distribution by Year of Establishment
Figure 5.8 Clinical Trial Planning and Design (Non-Industry Players): Distribution by Company Size
Figure 5.9 Clinical Trial Planning and Design (Non-Industry Players): Distribution by Location of Headquarters
Figure 5.10 Clinical Trial Planning and Design (Non-Industry Players): Distribution by Type of Service Offered
Figure 6.1 Company Competitiveness: North America
Figure 6.2 Company Competitiveness: Europe
Figure 6.3 Company Competitiveness: Asia-Pacific and RoW
Figure 7.1 PharmaLex: Service Portfolio
Figure 7.2 Health Policy Associates: Service Portfolio
Figure 7.3 CD Biosciences: Service Portfolio
Figure 7.4 Emergo: Service Portfolio
Figure 7.5 Cytel: Service Portfolio
Figure 7.6 Biop: Service Portfolio
Figure 7.7 Staburo: Service Portfolio
Figure 7.8 Algorics: Service Portfolio
Figure 7.9 LLX Solutions: Service Portfolio
Figure 7.10 Pragrathan: Service Portfolio
Figure 8.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3Partnerships and Collaborations: Distribution by Year and Type of Partnership 
Figure 8.4. Partnerships and Collaborations: Distribution by Focus Area
Figure 8.5 Most Active Players: Distribution by Number of Partnerships
Figure 8.6 Partnerships and Collaborations: Distribution by Geography
Figure 8.7Partnerships and Collaborations: Country-wise Distribution
Figure 8.8Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 9.1 Mergers and Acquisitions: Distribution by Year of Agreement
Figure 9.2 Mergers and Acquisitions: Distribution by Type of Agreement
Figure 9.3 Mergers and Acquisitions: Distribution by Type of Acquisition
Figure 9.4 Mergers and Acquisitions: Distribution by Geography
Figure 9.5 Mergers and Acquisitions: Region-wise Distribution
Figure 9.6 Mergers and Acquisitions: Country-wise Distribution
Figure 9.7 Mergers and Acquisitions: Ownership Change Matrix
Figure 9.8 Mergers and Acquisitions: Distribution by Key Value Drivers
Figure 9.9 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
Figure 10.1 AC Matrix: North America Scenario
Figure 10.2 AC Matrix: Europe Scenario
Figure 10.3 AC Matrix: Asia Pacific and RoW Scenario
Figure 11.1 Overall Cost Saving Potential of Clinical Trial Planning and Design, 2021-2030 (USD Million)
Figure 12.1 Global Clinical Trial Planning and Design Services Market, 2021-2030 (USD Million)
Figure 12.2 Global Clinical Trial Planning and Design Services Market: Distribution by Type of Service Offered, 2021-2030 (USD Million)
Figure 12.3 Global Clinical Trial Planning and Design Services Market: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Figure 12.4 Global Clinical Trial Planning and Design Services Market: Distribution by Trial Phase, 2021-2030 (USD Million)
Figure 12.5 Global Clinical Trial Planning and Design Services Market: Distribution by Geography, 2021-2030 (USD Million)
Figure 12.6 Global Clinical Trial Planning and Design Services Market: Distribution by Type of Service, 2021-2030 (USD Million)
Figure 12.7 Clinical Trial Planning and Design Services Market in North America, 2021-2030 (USD Million)
Figure 12.8 Clinical Trial Planning and Design Services Market for Oncological Disorders in North America, 2021-2030 (USD Million)
Figure 12.9 Clinical Trial Planning and Design Services Market for Neurological Disorders in North America, 2021-2030 (USD Million)
Figure 12.10 Clinical Trial Planning and Design Services Market for Infectious Disorders in North America, 2021-2030 (USD Million)
Figure 12.11 Clinical Trial Planning and Design Services Market for Autoimmune Disorders in North America, 2021-2030 (USD Million)
Figure 12.12 Clinical Trial Planning and Design Services Market for Cardiovascular Disorders in North America, 2021-2030 (USD Million)
Figure 12.13 Clinical Trial Planning and Design Services Market for Respiratory Disorders in North America, 2021-2030 (USD Million)
Figure 12.14 Clinical Trial Planning and Design Services Market for Other Disorders in North America, 2021-2030 (USD Million)
Figure 12.15 Clinical Trial Planning and Design Services Market in Europe, 2021-2030 (USD Million)
Figure 12.16 Clinical Trial Planning and Design Services Market for Oncological Disorders in Europe, 2021-2030 (USD Million)
Figure 12.17 Clinical Trial Planning and Design Services Market for Neurological Disorders in Europe, 2021-2030 (USD Million)
Figure 12.18 Clinical Trial Planning and Design Services Market for Infectious Disorders in Europe, 2021-2030 (USD Million)
Figure 12.19 Clinical Trial Planning and Design Services Market for Autoimmune Disorders in Europe, 2021-2030 (USD Million)
Figure 12.20 Clinical Trial Planning and Design Services Market for Cardiovascular Disorders in Europe, 2021-2030 (USD Million)
Figure 12.21 Clinical Trial Planning and Design Services Market for Respiratory Disorders in Europe, 2021-2030 (USD Million)
Figure 12.22 Clinical Trial Planning and Design Services Market for Other Disorders in Europe, 2021-2030 (USD Million)
Figure 12.23 Clinical Trial Planning and Design Services Market in Asia-Pacific, 2021-2030 (USD Million)
Figure 12.24 Clinical Trial Planning and Design Services Market for Oncological Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 12.25 Clinical Trial Planning and Design Services Market for Neurological Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 12.26 Clinical Trial Planning and Design Services Market for Infectious Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 12.27 Clinical Trial Planning and Design Services Market for Autoimmune Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 12.28 Clinical Trial Planning and Design Services Market for Cardiovascular Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 12.29 Clinical Trial Planning and Design Services Market for Respiratory Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 12.30 Clinical Trial Planning and Design Services Market for Other Therapeutic Areas in Asia-Pacific, 2021-2030 (USD Million)
Figure 12.31 Clinical Trial Planning and Design Services Market in Latin America, 2021-2030 (USD Million)
Figure 12.32 Clinical Trial Planning and Design Services Market in Middle East North America, 2021-2030 (USD Million)
Figure 13.1 SWOT Analysis: Overview
Figure 14.1 Clinical Trial Planning and Design: Conclusion

List Of Tables

Table 3.1 Characteristic Features of Clinical Trial
Table 4.1 Regulatory and Ethics Requirements Across Various Geographies
Table 5.1 Clinical Trial Planning and Design: List of Industry Players
Table 5.2 Clinical Trial Planning and Design: List of Non-Industry Players
Table 6.1 Clinical Trial Planning and Design: Company Competitiveness Analysis
Table 7.1 PhamaLex: Company Overview
Table 7.2 PharmaLex: Future Outlook
Table 7.3 Health Policy Associates: Company Overview
Table 7.4 CD Biosciences: Company Overview
Table 7.5 Emergo: Company Overview
Table 7.6 Cytel: Company Overview
Table 7.7 Cytel: Future Outlook
Table 7.8 Biop: Company Overview
Table 7.9 Biop: Future Outlook
Table 7.10 Staburo: Company Overview
Table 7.11 Staburo: Future Outlook
Table 7.12 Algorics: Company Overview
Table 7.13 Algorics: Future Outlook
Table 7.14 LLX Solutions: Company Overview
Table 7.15 LLX Solutions: Future Outlook
Table 7.16 Pragrathan: Company Overview
Table 7.17 Pragrathan: Future Outlook
Table 8.1 Clinical Trial Planning and Design: List of Partnerships and Collaborations, 2016-2021
Table 9.1 Clinical Trial Planning and Design: List of Mergers and Acquisitions, 2016-2021
Table 9.2 Clinical Trial Planning and Design: Information on Key Value Drivers, 2016- 2021
Table 13.1 Harvey Ball Analysis: Clinical Trial Planning and Design Service Providers
Table 17.1 Clinical Trial Planning and Design (Industry Players): Analysis by Year of Establishment
Table 17.2 Clinical Trial Planning and Design (Industry Players): Analysis by Company Size
Table 17.3 Clinical Trial Planning and Design (Industry Players): Analysis by Location of Headquarters
Table 17.4 Clinical Trial Planning and Design (Industry Players): Analysis by Type of Product
Table 17.5 Clinical Trial Planning and Design (Industry Players): Analysis by Type of Trial Design
Table 17.6 Clinical Trial Planning and Design (Industry Players): Analysis by Type of Service Offered
Table 17.7 Clinical Trial Planning and Design (Non-Industry Players): Analysis by Year of Establishment
Table 17.8 Clinical Trial Planning and Design (Non-Industry Players): Analysis by Company Size
Table 17.9 Clinical Trial Planning and Design (Non-Industry Players): Analysis by Location of Headquarters
Table 17.10 Clinical Trial Planning and Design (Non-Industry Players): Analysis by Type of Service Offered
Table 17.11 Company Competitiveness: North America
Table 17.12 Company Competitiveness: Europe
Table 17.13 Company Competitiveness: Asia-Pacific and RoW
Table 17.14 Partnerships and Collaborations: Analysis by Year of Partnership
Table 17.15 Partnerships and Collaborations: Analysis by Type of Partnership
Table 17.16 Partnerships and Collaborations: Analysis by Year and Type of Partnership
Table 17.17 Partnerships and Collaborations: Analysis by Focus Area
Table 17.18 Most Active Players: Analysis by Number of Partnerships
Table 17.19 Partnerships and Collaborations: Analysis by Geography
Table 17.20 Partnerships and Collaborations: Country-wise Distribution
Table 17.21 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Table 17.22 Mergers and Acquisitions: Analysis by Year of Agreement
Table 17.23 Mergers and Acquisitions: Analysis by Type of Agreement
Table 17.24 Mergers and Acquisitions: Analysis by Type of Acquisition
Table 17.25 Mergers and Acquisitions: Analysis by Geography
Table 17.26 Mergers and Acquisitions: Region-wise Distribution
Table 17.27 Mergers and Acquisitions: Country-wise Distribution
Table 17.28 Mergers and Acquisitions: Ownership Type Change Matrix
Table 17.29 Mergers and Acquisitions: Analysis by Key Value Drivers
Table 17.30 Mergers and Acquisitions: Analysis by Year of Acquisition and Key Value Drivers
Table 17.31 AC Matrix: Clinical Planning and Design Scenario in North America
Table 17.32 AC Matrix: Clinical Planning and Design Scenario in Europe
Table 17.33 AC Matrix: Clinical Planning and Design Scenario in Asia Pacific and Middle East
Table 17.34 Overall Cost Saving Potential of Clinical Trial Planning and Design, 2021-2030 (USD Million)
Table 17.35 Global Clinical Trial Planning and Design Services Market, 2021-2030 (USD Million)
Table 17.36 Global Clinical Trial Planning and Design Services Market: Distribution by Type of Service Offered, 2021-2030 (USD Million)
Table 17.37 Global Clinical Trial Planning and Design Services Market: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Table 17.38 Global Clinical Trial Planning and Design Services Market: Distribution by Trial Phase, 2021-2030 (USD Million)
Table 17.39 Global Clinical Trial Planning and Design Services Market: Distribution by Geography, 2021-2030 (USD Million)
Table 17.40 Global Clinical Trial Planning and Design Services Market: Distribution by Type of Service, 2021-2030 (USD Million)
Table 17.41 Clinical Trial Planning and Design Services Market in North America, 2021-2030 (USD Million)
Table 17.42 Clinical Trial Planning and Design Services Market for Oncological Disorders in North America, 2021-2030 (USD Million)
Table 17.43 Clinical Trial Planning and Design Services Market for Neurological Disorders in North America, 2021-2030 (USD Million)
Table 17.44 Clinical Trial Planning and Design Services Market for Infectious Disorders in North America, 2021-2030 (USD Million)
Table 17.45 Clinical Trial Planning and Design Services Market for Autoimmune Disorders in North America, 2021-2030 (USD Million)
Table 17.46 Clinical Trial Planning and Design Services Market for Cardiovascular Disorders in North America, 2021-2030 (USD Million)
Table 17.47 Clinical Trial Planning and Design Services Market for Respiratory Disorders in North America, 2021-2030 (USD Million)
Table 17.48 Clinical Trial Planning and Design Services Market for Other Disorders in North America, 2021-2030 (USD Million)
Table 17.49 Clinical Trial Planning and Design Services Market in Europe, 2021-2030 (USD Million)
Table 17.50 Clinical Trial Planning and Design Services Market for Oncological Disorders in Europe, 2021-2030 (USD Million)
Table 17.51 Clinical Trial Planning and Design Services Market for Neurological Disorders in Europe, 2021-2030 (USD Million)
Table 17.52 Clinical Trial Planning and Design Services Market for Infectious Disorders in Europe, 2021-2030 (USD Million)
Table 17.53 Clinical Trial Planning and Design Services Market for Autoimmune Disorders in Europe, 2021-2030 (USD Million)
Table 17.54 Clinical Trial Planning and Design Services Market for Cardiovascular Disorders in Europe, 2021-2030 (USD Million)
Table 17.55 Clinical Trial Planning and Design Services Market for Respiratory Disorders in Europe, 2021-2030 (USD Million)
Table 17.56 Clinical Trial Planning and Design Services Market for Other Disorders in Europe, 2021-2030 (USD Million)
Table 17.57 Clinical Trial Planning and Design Services Market in Asia-Pacific, 2021-2030 (USD Million)
Table 17.58 Clinical Trial Planning and Design Services Market for Oncological Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 17.59 Clinical Trial Planning and Design Services Market for Neurological Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 17.60 Clinical Trial Planning and Design Services Market for Infectious Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 17.61 Clinical Trial Planning and Design Services Market for Autoimmune Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 17.62 Clinical Trial Planning and Design Services Market for Cardiovascular Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 17.63 Clinical Trial Planning and Design Services Market for Respiratory Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 17.64 Clinical Trial Planning and Design Services Market for Other Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 17.65 Clinical Trial Planning and Design Services Market in Latin America, 2021-2030 (USD Million)
Table 17.66 Clinical Trial Planning and Design Services Market in Middle East North America, 2021-2030 (USD Million)

List Of Companies

The following companies and organizations have been mentioned in the report.

  1. ACI Clinical
  2. ADM Korea
  3. Alacrita
  4. Algorics
  5. Alison Heald Consulting
  6. Anju Software
  7. Armstrong Clinical
  8. AstraCrux Clinical Trial and Consulting
  9. Axeon Biomedicine Globalization
  10. Berry Consultants
  11. BioDebug 
  12. BioepiNet
  13. BioGenesis Health Cluster
  14. Biologics Consulting
  15. Biomedical Consulting International
  16. Biop
  17. BioPoint
  18. Biostatistics Consulting Center
  19. Blueprint Software Systems
  20. Boston Children's Hospital
  21. Brigham and Women's Hospital
  22. Cancer Research And Biostatistics
  23. CARe KERALAM
  24. CATO SMS
  25. CD BioSciences
  26. Celgene
  27. Center for Clinical and Translational Science and Training
  28. Center for Innovative Study Design (CSID)
  29. Cerba Research
  30. Cerba Xpert
  31. Chesapeake Biotech Partners
  32. Children's Hospital of Philadelphia
  33. CIMS
  34. ClinAsia
  35. CliniOps
  36. CMD Consulting
  37. Copyright Clearance Center
  38. Cystic Fibrosis Foundation
  39. Cytel
  40. DATAMEDICA
  41. Data Coordination Unit
  42. Public Health Sciences (The University of Chicago)
  43. Duke-NUS
  44. eClinical Solutions
  45. Eclipse
  46. Elevation Strategic Development
  47. Elm Tree Research
  48. Emergo
  49. EpidStrategiess
  50. EvidNet
  51. ExperiMind Technologies
  52. Exploristics
  53. FGK Clinical Research
  54. Foundation Medicine
  55. Fred Hutchinson Cancer Research Center
  56. Galapagos
  57. Generis
  58. Georgetown-Howard Universities Center for Clinical and Translational Science
  59. Georgia Clinical & Translational Science Alliance
  60. Global Clinical Trial Partners
  61. GNS Healthcare
  62. Halloran
  63. Health Policy Associate
  64. Hict
  65. HISTALIM
  66. HRB Clinical Research facility Galway
  67. Hunter Medical Research Institute (HMRI)
  68. IGES Institut
  69. Innoplexus
  70. Insightful Science
  71. Interdisciplinary Health Sciences
  72. International Society of Nephrology
  73. Intertek
  74. intilaris LifeSciences
  75. Irving Institute for Clinical and Translational Research
  76. IRYCIS
  77. Istesso
  78. karmadata
  79. KINGROCK
  80. Laiya Consulting
  81. Leoben Research
  82. LLX Solutions
  83. LMK Clinical Research Consulting
  84. Matrix Healthcare Solutions
  85. MB Clinical Research and Consulting
  86. McKesson
  87. MDC Partners
  88. MED Institute
  89. MedAvante - ProPhase
  90. Meditix
  91. Mednet Solutions
  92. MEPHARMA
  93. Merigold Partners
  94. Milken Institute 
  95. Narayana Health
  96. National Jewish Health
  97. NC TraCS
  98. NDA Partners
  99. NEW Drug Development Paradigms (NEWDIGS)
  100. New Mountain Capital
  101. Northwestern University
  102. Novadiscovery
  103. Nurocor
  104. Nuventra
  105. NYU Langone Health
  106. OHSU Knight Cancer Institute
  107. Ology Universal Research Solutions
  108. OpenQ
  109. Optimax Access
  110. Optus Research & Analytics
  111. OWL Metabolomics
  112. Paladin Medical
  113. Parkland Hospital
  114. Peter MacCallum Cancer Centre
  115. Pfizer
  116. PharmaLex
  117. Phesi
  118. Pitt’s Clinical and Translational Science Institute
  119. Praedicare 
  120. Pragrathan
  121. Pubrica 
  122. Quantics Biostatistics
  123. Quartesian
  124. Remarque Systems
  125. Rio Pharmaceutical Services
  126. Rutgers Cancer Institute of New Jersey 
  127. Rutgers School of Public Health
  128. RW Malone
  129. Sensyne Health
  130. SGS
  131. Signa Medical Writing
  132. Singapore Clinical Research Institute
  133. SK Reddy
  134. Spectro Decypher
  135. SQN Clinical
  136. Staburo
  137. Statiza Statistical Services
  138. Statsols
  139. Statswork
  140. Stone Biostatistics
  141. Takeda Pharmaceutical
  142. The Center for Cancer Biostatistics (University of Michigan School of Public    Health)
  143. The Ohio State University
  144. Thomas Jefferson University
  145. ThreeWire
  146. TriNetX
  147. Tufts CTSI
  148. UC Davis Health
  149. UC Health 
  150. UC Irvine
  151. University of Arizona College of Medicine
  152. University of Kentucky
  153. University of lowa
  154. University of Melbourne
  155. University of Tennessee Health Science Center
  156. UT Health San Antonio
  157. Valos
  158. Veeva Systems
  159. Venn Life Sciences
  160. Vintura
  161. Waife & Associates
  162. Washington University in St. Louis
  163. Wayne State University
  164. WCG
  165. Weill Cornell Medicine
  166. Wemedoo
  167. West Virginia Clinical and Translational Science Institute
  168. Wound Market Consulting
  169. Yale Center for Clinical Investigation
  170. Zephyr Health

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com